Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study

ATBC队列随访研究自1994年以来一直在进行。男性吸烟者 1985年4月至1988年6月，从芬兰西南部招募了50至69岁的志愿者。一 共有29，133名男性被随机分配到四个干预组之一：50 mg/天 α-生育酚（以dl-α-生育酚乙酸酯计）; 20 mg/天β-胡萝卜素;两者 α-生育酚和β-胡萝卜素;或安慰剂。他们被跟踪了五到八年 试验期间，直至死亡，或1993年4月30日干预停止（中位数 随访6.1年）。干预后继续对终点进行随访。以下 邀请参与和通过人口为基础的邮政调查招募， 试验随机分配了29，133名50 - 69岁的高加索男性吸烟者，每天吸烟5支 基于2 × 2析因设计的四个干预组之一：β-胡萝卜素（20 mg/天）， 维生素E（50 mg/天，作为dl-α-生育酚乙酸酯）、两种药剂或安慰剂。在入口处， 获得了医疗、饮食、吸烟和职业方面的数据，沿着的还有体格检查。 测量，胸部X光，血清和脚趾甲样本。饮食是通过一个276 食物项目饮食调查表，该调查表是为试验开发和验证的。基线血清 收集，冷冻，并储存所有参与者，维生素E，β-胡萝卜素，视黄醇， 并测定总胆固醇和高密度脂蛋白胆固醇。收集随访血清和全血 对于研究后期的所有活跃参与者， 从选定的子集的样本。积极干预持续了5 - 8年，有三项研究 每年进行一次访问，期间询问参与者的健康状况， 自上次访视以来的主观副作用、胶囊依从性和吸烟习惯。胸部 每隔2 - 3年和试验结束时拍摄电影。所有癌症病例均为 通过芬兰全国癌症登记处、医疗记录/病理学 SLI

The ATBC Cohort Follow-up Study has been in place since 1994. Male smokers between the ages of 50 and 69 were recruited from southwestern Finland between April 1985 and June 1988. A total of 29,133 men were randomly assigned to one of four intervention groups: 50 mg/day alpha-tocopherol (as dl-alpha-tocopheryl acetate); 20 mg/day beta-carotene; both alpha-tocopherol and beta-carotene; or placebo. They were followed for five to eight years during the trial, until death, or 30 April 1993 when intervention was stopped (median follow-up, 6.1 years). Follow-up for endpoints was continued postintervention. Following invitation for participation and recruitment through a population-based postal survey, the trial randomly assigned 29,133 Caucasian 50-69 year old male smokers of 5 cigarettes daily to one of four intervention groups based on a 2x2 factorial design: beta-carotene (20 mg/day), vitamin E (50 mg/day, as dl-alpha-tocopheryl acetate), both agents, or placebo. At entry, medical, dietary, smoking, and occupational data were obtained, along with physical measurements, a chest x-ray, and serum and toenail samples. Diet was captured through a 276 food item dietary questionnaire that was developed and validated for the trial. Baseline serum was collected, frozen, and stored for all participants, and vitamin E, beta-carotene, retinol, and total and HDL cholesterol were determined. Follow-up serum and whole blood were collected for all active participants later in the study, as were additional serum and red blood cell samples from selected subsets. Active intervention continued for 5-8 years, with three study visits annually during which participants were asked about their health and possible subjective side effects, capsule compliance, and smoking habits since the last visit. Chest films were taken at 2-3 year intervals and at the end of the trial. All incident cancers were identified through the nationwide Finnish Cancer Registry, medical records/pathology sli